Allergic Rhinitis Market 2034

The Allergic Rhinitis market report also offers comprehensive insights into the Allergic Rhinitis market size, share, Allergic Rhinitis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Allergic Rhinitis market size growth forward.

Some of the key highlights from the Allergic Rhinitis Market Insights Report:

• Several key pharmaceutical companies, including Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics,Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, and others, are developing novel products to improve the Allergic Rhinitis treatment outlook.

• In November 2024, Keymed Biosciences Co. Ltd. initiated a randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of Stapokibart injection in patients with allergic rhinitis. Allergic rhinitis (AR) is a chronic inflammatory condition of the nasal mucosa, primarily mediated by immunoglobulin E (IgE) in atopic individuals exposed to allergens.

• In the same month, Wecare Probiotics Co. Ltd. began a study to assess the effectiveness of Weizmannia Coagulans BC99 in alleviating allergic rhinitis symptoms in adults. The study also aims to evaluate its impact on the gut microbiota and its potential to reduce adverse reactions in patients.

• In 2023, the United States had the largest Allergic Rhinitis market size among the 7MM, valued at approximately USD 3,600 million, with projections indicating further growth by 2034.

• Japan recorded the highest prevalence of Allergic Rhinitis among the 7MM in 2023, with around 65 million cases, a number expected to rise by 2034.

• The emerging drug REGN5713-5714-5715 is anticipated to launch in EU4 and the UK by 2025, followed by Japan in 2026, offering potential relief and reducing the disease burden in the coming years.

• As per DelveInsight analysis, the Allergic Rhinitis market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Allergic Rhinitis Market Landscape

Allergic Rhinitis Overview

Allergic rhinitis is an atopic condition characterized by sneezing, nasal congestion, clear rhinorrhea, and nasal itching. It involves an IgE-mediated immune response to inhaled allergens in the immediate phase, followed by a leukotriene-mediated late phase. Proper evaluation and treatment are essential, with an interprofessional team playing a crucial role in improving patient care.

The condition is classified based on the triggering allergen (seasonal, perennial, or episodic), symptom frequency (intermittent or persistent), and severity (ranging from mild to severe).

Risk factors include exposure to pollen (trees, grass, and weeds like ragweed), indoor allergens (dust mites, pet dander), proteins, chemicals, antibiotic use, air pollution, farm animals (in LMICs), household pets, parental smoking, and intense physical activity in adolescents.

Common symptoms include rhinorrhea, nasal itching, sneezing, and congestion, often accompanied by allergic conjunctivitis, itchy ears and palate, and asthma. Diagnosis is typically supported by a correlation between clinical history and allergen sensitization.

Do you know the treatment paradigms for different countries? Download our Allergic Rhinitis Market Sample Report

Allergic Rhinitis Epidemiology Insights

• According to DelveInsight’s assessment, the total estimated diagnosed prevalent cases of allergic rhinitis in the 7MM were approximately 90 million in 2023.

Allergic Rhinitis Epidemiology Segmentation

DelveInsight’s Allergic Rhinitis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Allergic Rhinitis historical patient pools and forecasted Allergic Rhinitis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Allergic Rhinitis Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

• Allergic Rhinitis Prevalence

• Age-Specific Allergic Rhinitis Prevalence

• Gender-Specific Allergic Rhinitis Prevalence

• Diagnosed and Treatable Cases of Allergic Rhinitis

Visit for more @ Allergic Rhinitis Epidemiological Insights

Allergic Rhinitis Market Outlook

The primary goal in treating allergic rhinitis is to alleviate symptoms. Treatment options to achieve this include avoidance of allergens, nasal saline irrigation, oral antihistamines, intranasal corticosteroids, combined intranasal corticosteroid/antihistamine sprays, leukotriene receptor antagonists (LTRAs), and allergen immunotherapy.

A full range of pharmacological treatments for allergic rhinitis includes both FDA-approved and off-label options. For mild cases, nasal washes can help clear mucus. Off-label treatments such as antihistamines are effective for occasional symptoms and can also be used as nasal sprays. Corticosteroid nasal sprays are the most effective treatment and work best with continuous use, although they are also useful for shorter or intermittent periods. These sprays are safe for both children and adults and come in various prescription and off-label brands. Decongestants can also help alleviate nasal congestion.

Additional treatments include leukotriene inhibitors, which block chemicals that trigger symptoms. Immunotherapy, including allergy shots, may be recommended for more challenging symptoms, offering regular doses of allergens to help the body adjust. Sublingual Immunotherapy Treatment (SLIT), which involves placing medicine under the tongue, can also be effective for grass and ragweed allergies.

Allergic Rhinitis Marketed Drugs

• RYALTRIS (Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray): Glenmark Pharmaceuticals Inc.

Allergic Rhinitis Emerging Drugs

• REGN5713-5714-5715: Regeneron Pharmaceuticals

• Grass MATA MPL: Allergy Therapeutics

Allergic Rhinitis Key Companies

• Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics,Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, and others

For more information, visit Allergic Rhinitis Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Allergic Rhinitis Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Allergic Rhinitis, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Allergic Rhinitis epidemiology in the 7MM

• Allergic Rhinitis marketed and emerging therapies

• Allergic Rhinitis companies

• Allergic Rhinitis market drivers and barriers

Table of Contents:

1 Allergic Rhinitis Market Key Comprehensive Insights

2 Allergic Rhinitis Market Report Introduction

3 Competitive Intelligence Analysis for Allergic Rhinitis

4 Allergic Rhinitis Market Analysis Overview at a Glance

5 Executive Summary of Allergic Rhinitis

6 Allergic Rhinitis Epidemiology and Market Methodology

7 Allergic Rhinitis Epidemiology and Patient Population

8 Allergic Rhinitis Patient Journey

9 Allergic Rhinitis Treatment Algorithm, Allergic Rhinitis Current Treatment, and Medical Practices

10 Key Endpoints in Allergic Rhinitis Clinical Trials

11 Allergic Rhinitis Marketed Therapies

12 Allergic Rhinitis Emerging Therapies

13 Allergic Rhinitis: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Allergic Rhinitis

16 Allergic Rhinitis Market Key Opinion Leaders Reviews

18 Allergic Rhinitis Market Drivers

19 Allergic Rhinitis Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Allergic Rhinitis Epidemiology 2034

DelveInsight’s “Allergic Rhinitis – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Allergic Rhinitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Allergic Rhinitis Pipeline 2024

“Allergic Rhinitis Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Allergic Rhinitis market. A detailed picture of the Allergic Rhinitis pipeline landscape is provided, which includes the disease overview and Allergic Rhinitis treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/